title: Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
authors.affiliation: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA. kellofg@mail.nih.gov
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: Robert C
authors.initials: RC
authors.lastname: Bast
authors.forename: Donald S
authors.initials: DS
authors.lastname: Coffey
authors.forename: Anthony V
authors.initials: AV
authors.lastname: D'Amico
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kerbel
authors.forename: John W
authors.initials: JW
authors.lastname: Park
authors.forename: Raymond W
authors.initials: RW
authors.lastname: Ruddon
authors.forename: Gordon J S
authors.initials: GJ
authors.lastname: Rustin
authors.forename: Richard L
authors.initials: RL
authors.lastname: Schilsky
authors.forename: Caroline C
authors.initials: CC
authors.lastname: Sigman
authors.forename: George F
authors.initials: GF
authors.lastname: Vande Woude
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor